Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Succinylcholine versus cisatracurium during electroconvulsive therapy
IRCT20160307026950N14Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of succinylcholine, cisatracurium and ketamine in mental disorder (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Serum potassium level. Started Mar 2019; status: completed.
02
Drugs
succinylcholinecisatracuriumketamine
03
Conditions
mental disorder
Beyond the preview
Go deeper on IRCT20160307026950N14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160307026950N14.